Visualising tapasin- and TAPBPR-assisted editing of major histocompatibility complex class-I immunopeptidomes.


Journal

Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118

Informations de publication

Date de publication:
08 2023
Historique:
received: 29 11 2022
revised: 21 04 2023
accepted: 21 04 2023
medline: 7 8 2023
pubmed: 29 5 2023
entrez: 28 5 2023
Statut: ppublish

Résumé

Which peptides are selected for presentation by major histocompatibility complex class-I (MHC-I) molecules is a key determinant of successful immune responses. Peptide selection is co-ordinated by the tapasin and TAP Binding PRotein (TAPBPR) proteins, which ensure MHC-I molecules preferentially acquire high-affinity-binding peptides. New structural analyses have offered insight into how tapasin achieves this function within the peptide-loading complex (PLC) (comprising the Transporter associated with Antigen Presentation (TAP) peptide transporter, tapasin-ERp57, MHC-I and calreticulin), and how TAPBPR performs a peptide editing function independently of other molecules. The new structures reveal nuances in how tapasin and TAPBPR interact with MHC-I, and how calreticulin and ERp57 complement tapasin to exploit the plasticity of MHC-I molecules to achieve peptide editing.

Identifiants

pubmed: 37245412
pii: S0952-7915(23)00059-6
doi: 10.1016/j.coi.2023.102340
pii:
doi:

Substances chimiques

tapasin 0
Calreticulin 0
Carrier Proteins 0
Histocompatibility Antigens Class I 0
Peptides 0
HLA Antigens 0
Immunoglobulins 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102340

Subventions

Organisme : Cancer Research UK
ID : A28279
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Andy van Hateren (A)

Institute for Life Sciences and Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Building 85, Southampton SO17 1BJ, UK.

Tim Elliott (T)

Centre for Immuno-oncology and CAMS-Oxford Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Headington, Oxford OX3 7BN, UK. Electronic address: tim.elliott@ndm.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH